ľֱ

Let's Talk Drug Prices; Restoring the Sense of Touch; Learning From Tumors in a Dish

— News, features, and commentary about cancer-related issues

MedpageToday
Onco Break over a computer rendering of a cancer cell.

Sen. Bernie Sanders (I-Vt.) has invited CEOs of Johnson & Johnson, Merck, and Bristol Myers Squibb to testify next month at a , specifically to discuss why the U.S. pays so much more than other countries for the same drugs. (Endpoints News)

Black men with are less likely than white men to receive novel hormonal therapies, despite having a significantly higher prostate cancer incidence and mortality. (UCLA Health Jonsson Comprehensive Cancer Center, JAMA Network Open)

The FDA announced that Bayer has agreed to a of the cancer drug larotrectinib (Vitrakvi) 20 mg/mL oral solution because of a risk of bacterial contamination.

Researchers will begin testing an implantable device that may following reconstructive surgery for breast cancer. (Case Western Reserve, University of Chicago)

The risk of in Mexican Americans continues to increase with each successive generation. (Cancer)

A computerized improved its predictive accuracy with the addition of new factors that include body mass index and second-degree relatives with a history of breast cancer. (University of California San Francisco, Journal of Clinical Oncology)

will increase by almost 2% per year for at least the next decade. (GlobalData)

Adding to evidence to support expanded use of , a study of lung cancer patients showed that about 15% have gene variants that may increase the risk of developing the cancer, even in people with no personal or family history of lung cancer. (JCO Precision Oncology)

Almost twice as many patients with myelofibrosis had at least a when treated with the bromodomain and extra-terminal inhibitor pelabresib plus the Janus kinase inhibitor ruxolitinib (Jakafi) as compared with ruxolitinib alone, MorphoSys announced.

Growing "micro tumors" in a laboratory dish may improve identification of . (University of Illinois Chicago)

  • author['full_name']

    Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined ľֱ in 2007.